Efficacy News and Research

RSS

Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder

AstraZeneca has announced important new data at the 4th European Stanley Foundation Conference on Bipolar Disorder, which show Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder and is also well-tolerated in this difficult to treat patient population.

26 Sep 2004

Low-dose infusion of ketamine completely relieves pain of complex regional pain syndrome

Limited, low-dose infusions of a widely used anesthetic drug may relieve the often intolerable and debilitating pain of Complex Regional Pain Syndrome (CRPS), a Penn State Milton S. Hershey Medical Center researcher found.

23 Sep 2004

Pneumonia could be treatable by the oral antibiotic amoxicillin rather than injectable penicillin

Pneumonia - one of the world’s deadliest diseases for young children in developing countries - could be treatable by the oral antibiotic amoxicillin rather than injectable penicillin, with implications for better health outcomes and reduced costs

23 Sep 2004

Edible vaccine for HIV AIDS

Scientists from Novosibirsk are engaged in the development of an unusual vaccine which, apart from being less expensive to produce, safe and painless to administer, is also edible.

22 Sep 2004

University of Arizona spin-off investigates DNA damage to human skin

Niadyne, Inc., a Tucson-based spin-off biopharmaceutical company co-founded by two University of Arizona professors, has received a Small Business Innovation Research grant of nearly $750,000 to continue investigating the prevention of DNA damage to human skin

22 Sep 2004

Novel strategy for stimulating the production of utrophin

Researchers at the University of Pennsylvania School of Medicine report a novel strategy for stimulating the production of utrophin – an important muscle protein in young mice – for muscular dystrophy therapy.

21 Sep 2004

Bonviva, to treat osteoporosis, submitted for marketing authorisation in Europe

Roche and GlaxoSmithKline announced today the submission of a Marketing Authorisation Application to the European authorities for a novel, once-monthly oral formulation of their new bisphosphonate, Bonviva (ibandronate), for the treatment of postmenopausal osteoporosis.

20 Sep 2004

European positive for Cymbalta and Xeristar

Eli Lilly and Company and Boehringer Ingelheim have announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment of major depressive episodes.

20 Sep 2004

Oral appliances effective in treating obstructive sleep apnea

Obstructive sleep apnea syndrome (OSAS) is a disorder characterized by repeated episodes of reductions or cessation in breathing during sleep. Millions of Americans, both men and women, have this medical problem

18 Sep 2004

A new lipid-based nasal ointment effective at reducing symptoms of allergic rhinitis

One in five Americans have allergic rhinitis, a number that is steadily rising, but the exact reasons for this increase are unknown. A new lipid-based nasal ointment is found effective at reducing symptoms of allergic rhinitis in German patients.

18 Sep 2004

Researchers find palatal implants provide effective snoring relief

Researchers find that inserting three matchstick sized pieces of polyester material in the upper palate is a simple, low cost, and easily tolerated office procedure that provides effective snoring relief.

17 Sep 2004

Inhaled nitrite spray may help babies diagnosed with persistent pulmonary hypertension of the newborn

Scientists from the National Institutes of Health (NIH) Clinical Center and the Loma Linda University School of Medicine have found that use of an inhaled nitrite spray may help babies diagnosed with persistent pulmonary hypertension of the newborn (PPHN).

13 Sep 2004

New treatment for T-cell acute lymphoblastic leukaemia

IL-7, a hormone-like protein involved in cell-cell interaction, has been associated with increased survival and expansion of T-cell acute lymphoblastic leukaemia (T-ALL).

9 Sep 2004

Exubera shows sustained blood glucose control in patients with type 2 diabetes

New data showed that Exubera (inhaled insulin) was effective and well tolerated in controlling blood glucose levels over a two-year period in patients with Type 2 diabetes.

8 Sep 2004

The drug galantamine has been shown to be ineffective in treating chronic fatigue syndrome

The drug galantamine (used for treatment of mild to moderate dementia) did not demonstrate a clinical benefit in treating chronic fatigue syndrome when compared with placebo, according to a study in the September 8 issue of JAMA.

8 Sep 2004

FDA approval for chewable ADHD tablets

Alliant Pharmaceuticals has announced FDA approval of Methylin Chewable Tablets and Methylin Oral Solution for the treatment of ADHD. The two products are the first, and only, chewable tablet and oral solution for ADHD to gain FDA acceptance.

7 Sep 2004

Ezetrol co-administration with statin therapy lowers LDL cholesterol in diabetics

Results from two new clinical trials show that patients with diabetes and metabolic syndrome who are treated with ezetimibe (EZETROL®) co-administered with a statin experience greater reductions in LDL (“bad”) cholesterol, compared to patients taking a statin alone.

7 Sep 2004

Generic tritherapy can be used as a basic treatment for AIDS

A clinical trial, conducted in Cameroon by IRD researchers working with other organizations and supported by the ANRS, has demonstrated that one of the most common combinations currently deployed in Africa, using nevirapine, stavudine and lamivudine, satisfies these criteria.

5 Sep 2004

First Parkinson’s gene therapy patient well after 1 year suggesting that the therapy is safe and effective

The first ever patient to have undergone gene therapy for Parkinson’s appears to have come through phase I without a hitch, suggesting that the therapy is safe and effective, reports Marina Murphy in Chemistry & Industry.

2 Sep 2004

Benefit of using clot-busting drug tissue plasminogen activator (tPA) for ischemic stroke

An independent review of data from a landmark clinical trial has validated the benefit of using the clot-busting drug tissue plasminogen activator (tPA) for ischemic stroke, when given within three hours of symptom onset under a strict treatment protocol.